Triple-Negative Breast Cancer: A-BRAVE Trial Results - Avelumab Immunotherapy Extends Overall Survival
The A-BRAVE trial, has shown that while 1 year of avelumab immunotherapy after standard treatment didn’t improve disease-free survival, it did significantly extend overall survival in high-risk early Triple-negative breast cancer (TNBC) patients. This is a significant finding as TNBC is notoriously aggressive and difficult to treat. What's everyone's take on this? Does this change the standard of care for TNBC or will this be limited to high-risk patients? Any insights on how this might impact future research or treatment options?
Triple-Negative Breast Cancer: A-BRAVE Trial Results - Avelumab Immunotherapy Extends Overall Survival
The A-BRAVE trial, has shown that while 1 year of avelumab immunotherapy after standard treatment didn’t improve disease-free survival, it did significantly extend overall survival in high-risk early Triple-negative breast cancer (TNBC) patients. This is a significant finding as TNBC is notoriously aggressive and difficult to treat. What's everyone's take on this? Does this change the standard of care for TNBC or will this be limited to high-risk patients? Any insights on how this might impact future research or treatment options?
Comments (4)
Great news but I'm not sure it should be standard of care for all TNBC patients until we see more evidence of its effectiveness across all risk levels.
This is really promising for high-risk TNBC patients. I wonder how soon we'll see this incorporated into standard treatment guidelines.
Great news but I'm not sure it should be standard of care for all TNBC patients until we see more evidence of its effectiveness across all risk levels.
As a TNBC survivor, this gives me hope. I wonder if this will help reduce the risk of recurrence for those of us who are high-risk.
Related Threads
Scientists Stabilize Vitamin B1 Molecule in Water, Confirming 67-Year-Old Theory
Because you viewed 'Triple-Negative Breast Cancer: A-BRAVE Trial Results - Avelumab Immunotherapy Extends Overall Survival', this post shares 0 tag(s) and has recent engagement.
What is the average salary in Chicago and how does it compare to other major US cities?
Because you viewed 'Triple-Negative Breast Cancer: A-BRAVE Trial Results - Avelumab Immunotherapy Extends Overall Survival', this post shares 0 tag(s) and has recent engagement.
Vitacel Tablets: Good for mostly everyone, or be cautious?
Because you viewed 'Triple-Negative Breast Cancer: A-BRAVE Trial Results - Avelumab Immunotherapy Extends Overall Survival', this post shares 0 tag(s) and has recent engagement.
Humanoid Robots Smash Human World Record in Beijing Half-Marathon: China's Rapid Advancement in Robotics
Because you viewed 'Triple-Negative Breast Cancer: A-BRAVE Trial Results - Avelumab Immunotherapy Extends Overall Survival', this post shares 0 tag(s) and has recent engagement.
London on a Budget: Easy Tube Exploration, Free Attractions, and Foodie Heaven!
Because you viewed 'Triple-Negative Breast Cancer: A-BRAVE Trial Results - Avelumab Immunotherapy Extends Overall Survival', this post shares 0 tag(s) and has recent engagement.
Newest Threads
OpenAI Rumored to be Developing a Smartphone with MediaTek and Qualcomm, Potential End of Apps?
Starlink to Disable Precise GPS Location Feature via Local gRPC API Interface by May 20, 2026
Intel's Stock Soars as AI Demand Revives Chip Sales, CPUs 2.0...?
Tragic Death of Australian Student Zander Philogene Highlights the Danger of Meningococcal B
Apex - Charlize Theron's Outback Thriller: Worth the Watch or a Miss?
Surviving the TOEFL Exam: Tips and Tricks to Ace It
What are the most effective strategies for improving your IELTS score?
LG C5 2025 Review and Comparison with the New LG C6
Thinking of moving from New York to Vancouver – how do the day-to-day lives compare?